ATE539758T1 - Rnai-modulation des bcr-abl-fusionsgens und dessen verwendungen - Google Patents

Rnai-modulation des bcr-abl-fusionsgens und dessen verwendungen

Info

Publication number: ATE539758T1
Authority: AT; Austria
Prior art keywords: bcr; fusion gene; abl fusion; abl; rnai modulation
Prior art date: 2004-11-24

Application number

AT09007997T

Other languages

English (en)

Inventor

Philipp Hadwiger

Hans-Peter Vornlocher

Der Kuip Heiko Van

Original Assignee

Alnylam Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-11-24

Filing date

2005-11-23

Publication date

2012-01-15

2005-11-23 Application filed by Alnylam Pharmaceuticals Inc filed Critical Alnylam Pharmaceuticals Inc

2012-01-15 Application granted granted Critical

2012-01-15 Publication of ATE539758T1 publication Critical patent/ATE539758T1/de

Links

108091030071 RNAI Proteins 0.000 title 1
108010056708 bcr-abl Fusion Proteins Proteins 0.000 title 1
WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 abstract 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 2
108091034117 Oligonucleotide Proteins 0.000 abstract 1
238000012228 RNA interference-mediated gene silencing Methods 0.000 abstract 1
230000003828 downregulation Effects 0.000 abstract 1
230000009368 gene silencing by RNA Effects 0.000 abstract 1
108020004999 messenger RNA Proteins 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Public Health (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Physics & Mathematics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Communicable Diseases (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)

AT09007997T 2004-11-24 2005-11-23 Rnai-modulation des bcr-abl-fusionsgens und dessen verwendungen ATE539758T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US63087804P	2004-11-24	2004-11-24
US63240304P	2004-12-01	2004-12-01

Publications (1)

Publication Number	Publication Date
ATE539758T1 true ATE539758T1 (de)	2012-01-15

Family

ID=36647951

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT09007997T ATE539758T1 (de)	2004-11-24	2005-11-23	Rnai-modulation des bcr-abl-fusionsgens und dessen verwendungen

Country Status (7)

Country	Link
US (4)	US20060287264A1 (de)
EP (2)	EP2133081B1 (de)
JP (2)	JP2008521401A (de)
AT (1)	ATE539758T1 (de)
AU (1)	AU2005323303A1 (de)
CA (1)	CA2587697A1 (de)
WO (1)	WO2006073602A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2008109376A1 (en) *	2007-03-02	2008-09-12	Mdrna, Inc.	Nucleic acid compounds for inhibiting bcr-abl gene expression and uses thereof
CN103169568B (zh)	2007-03-13	2015-07-15	眼科医疗公司	用于创建切口以提高人工晶状体设置的装置
ITRM20070595A1 (it) *	2007-11-15	2009-05-16	Univ Roma	Mirna e sirna e loro uso in terapia
WO2009137872A1 (en) *	2008-05-14	2009-11-19	Simons Haplomics Limited	Methods and compositions for the treatment of cancer
WO2010141511A2 (en)	2009-06-01	2010-12-09	Halo-Bio Rnai Therapeutics, Inc.	Polynucleotides for multivalent rna interference, compositions and methods of use thereof
WO2017035278A1 (en)	2015-08-24	2017-03-02	Halo-Bio Rnai Therapeutics, Inc.	Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
CN106987599B (zh) *	2017-03-28	2021-06-11	重庆医科大学	一种抑制人bcr-abl融合基因表达或导致人bcr-abl基因功能丧失的锌指核酸酶及其应用
EP3640329A1 (de) *	2018-10-18	2020-04-22	Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO)	Geneditierungsbasierte krebsbehandlung

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5328470A (en) *	1989-03-31	1994-07-12	The Regents Of The University Of Michigan	Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
EP0590090A4 (de) *	1991-06-18	1995-04-12	Univ Temple	Selektive hemmung leukämischer zellproliferation durch -i(bcr-abl) antisens-oligonukleotide.
US5898031A (en) *	1996-06-06	1999-04-27	Isis Pharmaceuticals, Inc.	Oligoribonucleotides for cleaving RNA
CA2429814C (en) *	2000-12-01	2014-02-18	Thomas Tuschl	Rna interference mediating small rna molecules
EP1386004A4 (de) *	2001-04-05	2005-02-16	Ribozyme Pharm Inc	Modulation der mit der entzündungsausbreitung und dem neuritenauswuchs assoziierten genexpression unter verwendung von technologien auf nukleinsäurebasis
US20030130186A1 (en) *	2001-07-20	2003-07-10	Chandra Vargeese	Conjugates and compositions for cellular delivery
US20050159381A1 (en) *	2001-05-18	2005-07-21	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of chromosome translocation gene expression using short interfering nucleic acid (siNA)
DE10202419A1 (de)	2002-01-22	2003-08-07	Ribopharma Ag	Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens
AU2003219833A1 (en)	2002-02-20	2003-09-09	Sirna Therapeutics Inc.	RNA INTERFERENCE MEDIATED INHIBITION OF CHROMOSOME TRANSLOCATION GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US7923547B2 (en) *	2002-09-05	2011-04-12	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003295600A1 (en) *	2002-11-14	2004-06-15	Dharmacon, Inc.	Functional and hyperfunctional sirna
WO2004064737A2 (en)	2003-01-17	2004-08-05	Alnylam Pharmaceuticals	Therapeutics compositions
CA2518475C (en)	2003-03-07	2014-12-23	Alnylam Pharmaceuticals, Inc.	Irna agents comprising asymmetrical modifications
ES2702942T3 (es) *	2003-04-17	2019-03-06	Alnylam Pharmaceuticals Inc	Agentes de ARNi modificados
JP4991288B2 (ja)	2003-04-17	2012-08-01	アルナイラムファーマシューティカルズ，インコーポレイテッド	二本鎖ｉＲＮＡ剤、および二本鎖ｉＲＮＡ剤の対合の安定性を調節する方法。
AU2005247509C1 (en)	2004-05-27	2012-09-20	Alnylam Pharmaceuticals, Inc.	Nuclease resistant double-stranded ribonucleic acid

2005
- 2005-11-23 CA CA002587697A patent/CA2587697A1/en not_active Abandoned
- 2005-11-23 US US11/286,624 patent/US20060287264A1/en not_active Abandoned
- 2005-11-23 WO PCT/US2005/042489 patent/WO2006073602A2/en not_active Ceased
- 2005-11-23 EP EP09007997A patent/EP2133081B1/de not_active Expired - Lifetime
- 2005-11-23 AT AT09007997T patent/ATE539758T1/de active
- 2005-11-23 AU AU2005323303A patent/AU2005323303A1/en not_active Abandoned
- 2005-11-23 EP EP05857009A patent/EP1814597A4/de not_active Withdrawn
- 2005-11-23 JP JP2007543452A patent/JP2008521401A/ja active Pending
2008
- 2008-07-10 US US12/171,291 patent/US20080293662A1/en not_active Abandoned
2009
- 2009-07-27 US US12/510,128 patent/US7994307B2/en not_active Expired - Lifetime
2011
- 2011-06-22 US US13/166,657 patent/US20110251263A1/en not_active Abandoned
- 2011-07-15 JP JP2011157156A patent/JP2011201927A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
EP2133081A1 (de)	2009-12-16
US20080293662A1 (en)	2008-11-27
WO2006073602A2 (en)	2006-07-13
AU2005323303A1 (en)	2006-07-13
EP1814597A2 (de)	2007-08-08
CA2587697A1 (en)	2006-07-13
US20060287264A1 (en)	2006-12-21
US20100234446A1 (en)	2010-09-16
JP2008521401A (ja)	2008-06-26
WO2006073602A9 (en)	2006-09-28
EP1814597A4 (de)	2009-04-22
WO2006073602A3 (en)	2007-11-22
JP2011201927A (ja)	2011-10-13
US20110251263A1 (en)	2011-10-13
EP2133081B1 (de)	2012-01-04
US7994307B2 (en)	2011-08-09

Publication	Publication Date	Title
ATE544774T1 (de)	2012-02-15	Rnai-modulation von mll-af4 und verwendungen dafür
WO2006036916A3 (en)	2006-07-27	Rnai modulation of apob and uses thereof
WO2005044976A3 (en)	2006-02-23	Oligomeric compounds for use in gene modulation
NO20081884L (no)	2008-06-12	Modulasjon av glukagonreseptorekspresjon
NO20081883L (no)	2008-06-11	Modulasjon av glukokortikoidreseptorekspresjon
WO2004005460A3 (en)	2004-04-01	Antisense modulation of hmg-coa reductase expression
WO2006020768A3 (en)	2007-07-05	Chemically modified oligonucleotides
EP1828219A4 (de)	2008-07-23	Sirna-silencing von apolipoprotein b
WO2004011610A3 (en)	2004-09-30	Antisense modulation of polo-like kinase expression
DE602007013559D1 (de)	2011-05-12	Nanoteilchen zur abgabe von nukleinsäure
MXPA06012796A (es)	2007-05-09	Ciertas entidades quimicas, composiciones y metodos.
EP1629084A4 (de)	2008-01-16	Modulation der expression von c-reaktivem protein
EP1569695A4 (de)	2006-12-06	Antisense-modulationder apolipoprotein-b-expression
WO2004071407A3 (en)	2006-01-12	Antisense modulation of ptp1b expression
WO2005049630A3 (en)	2006-03-02	Antisense modulation of kinesin-like 1 expression
BRPI0413969A (pt)	2006-10-31	modulação da transcrição ativada por -catenina/tcf
WO2007056143A3 (en)	2007-11-29	Certain chemical entities, compositions, and methods
WO2003046132A3 (en)	2003-08-07	Antisense modulation of myd88 expression
WO2005049832A3 (en)	2006-04-20	FcϜRIIA-SPECIFIC NUCLEIC ACID INTERFERENCE
WO2007014077A3 (en)	2007-12-06	Rnai modulation of the rho-a gene and uses thereof
WO2003022222A3 (en)	2005-02-03	Antisense modulation of protein kinase r expression
WO2007056469A3 (en)	2007-11-15	Certain chemical entities, compositions, and methods
WO2007056078A3 (en)	2008-01-24	Certain chemical entities, compositions, and methods
ATE539758T1 (de)	2012-01-15	Rnai-modulation des bcr-abl-fusionsgens und dessen verwendungen
WO2009071680A3 (en)	2009-07-23	Rna antagonist compounds for the modulation of mcl-1